Privacy Group NOYB to Challenge Meta Over EU Data Use for AI

Published 10 hours agoMETA

Privacy Group NOYB to Challenge Meta Over EU Data Use for AI

Austrian privacy advocacy group NOYB, led by well-known activist Max Schrems, has announced its plans to pursue a legal injunction against Meta Platforms. The group is challenging Meta's use of personal data from European users on Facebook and Instagram for training its AI systems. This move represents an increasing scrutiny on how tech giants handle data amid growing concerns about user privacy rights.

The legal action targets Meta's practices, with NOYB setting a deadline of May 21 for Meta to respond to their cease and desist letter. According to a report by Reuters, Meta could face significant financial liabilities if it continues without adjusting its policies. The advocacy group suggests class action lawsuits could emerge, potentially involving up to 400 million users, each entitled to claim damages up to €500, accumulating to billions of euros in total damages.

As the regulatory landscape tightens in Europe, NOYB requests that Meta allow users to opt-in explicitly and ensures data anonymization in compliance with EU standards. Meta, on the other hand, maintains that its approach is aligned with the EU's 'legitimate interest' clause in privacy law. This clash highlights the growing friction between privacy regulations and technology company operations concerning AI development.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Sanara MedTech Reports 26% Revenue Surge and Expands Market Strategy

Sanara MedTech Reports 26% Revenue Surge and Expands Market Strategy

5 minutes agoSMTI

Sanara MedTech Inc. (SMTI) has reported a remarkable 26% increase in revenue, highlighting the company's strong financial performance. This growth comes amid various strategic developments aimed at enhancing its market presence and product line. In addition to its robust revenue growth, Sanara MedTech is planning to expand its operations significantly by reaching more than 1,450 facilities by the end of 2025. This ambitious expansion plan follows the company's recent pilot launch of its Therapeutic Healing Products (THP) line, which marks a pivotal step in its product development efforts. According to Reuters, these strategies might position Sanara as a competitive player in its industry. Despite these positive developments, Sanara MedTech's stock saw a decline, trading at $32.65 as of May 14, 2025, which is a drop of $2.45 or 6.98% from the previous closing. The company's focus remains on implementing its growth strategies effectively, as indicated by its ongoing expansion initiatives and product innovations.

Caleres Faces Earnings Shortfall and Stock Slide Amid Operational Hurdles

Caleres Faces Earnings Shortfall and Stock Slide Amid Operational Hurdles

35 minutes agoCAL

Caleres, a leading footwear retailer, is currently grappling with a tough financial period marked by disappointing third-quarter earnings and a sharp plunge in its stock value. The company revealed that its adjusted earnings per share reached $1.23, which fell short of the $1.38 expected by analysts. Likewise, Caleres' revenue figure of $740.9 million was below the anticipated $753.81 million and noted a 2.8% year-over-year decline. Following these results, Caleres revised its fiscal 2024 earnings guidance, now projecting earnings per share in the range of $3.45 to $3.55, a decrease from the former range of $4.00 to $4.15. Moreover, it expects net sales to shrink by 2.5% to 3%, a revision from its earlier forecast of a low single-digit percentage drop. These challenges were compounded by several operational obstacles, including reduced demand for boots, delayed athletic product shipments, and a specific customer credit issue. Additionally, CEO Jay Schmidt noted that business in China did not meet expectations. Reflecting this challenging environment, Caleres' stock tumbled 15.66% in premarket trading following the earnings announcement, as reported by Investing.com. These developments have also stirred interest from short sellers, indicating growing market skepticism regarding Caleres' immediate performance prospects.

AMD Ups Stock Buyback Plan by $6 Billion Amid Market Movements

AMD Ups Stock Buyback Plan by $6 Billion Amid Market Movements

50 minutes agoAMD

Advanced Micro Devices (AMD) has announced a new $6 billion stock buyback plan, raising its total share repurchase authority to approximately $10 billion. This move comes as AMD aims to assert its competitive stance in the semiconductor industry. Reuters reports that this decision boosted AMD's share prices by 6.4% shortly after the announcement, although the stock has dipped over 6% since the start of the year, lagging behind the broader semiconductor market. Despite the excitement surrounding the buyback, challenges persist for AMD. The company reported a drop in free cash flow over the first quarter of 2025 by more than 33%, falling to $727 million. Additionally, AMD's financial statements reveal that its liabilities have surpassed its cash holdings. These financial maneuvers align with broader industry trends, as rival firms like Broadcom and Qualcomm have also launched large buyback initiatives valued at $10 billion and $15 billion respectively. Lisa Su, AMD's CEO, emphasized the strategic rationale behind the buyback plan, highlighting the Board's confidence in the company's growth potential. This initiative follows a substantial $10 billion collaboration with Humain focused on AI, which places AMD among tech giants capitalizing on opportunities in the Middle East. Su's remarks reflect the company's focus on fostering long-term shareholder value and enhancing its market position.

E.l.f. Beauty Shares Plunge Amid Tariff Worries

E.l.f. Beauty Shares Plunge Amid Tariff Worries

E.l.f. Beauty's shares took a significant hit, dropping over 20% in extended trading. This decline follows the company's move to slash its annual sales and profit forecasts due to waning demand in the mass beauty market. Reuters reported that investor concerns have mounted due to the newly announced tariffs under President Donald Trump, which pose a risk to a company heavily reliant on Chinese manufacturing. Approximately 80% of E.l.f. Beauty's products are manufactured in China, and the new 10% tariff on Chinese imports has stirred worries. However, CEO Tarang Amin expressed some relief, pointing out that fears of much higher tariffs, potentially up to 60%, have not materialized. In response to prior tariffs, the company had raised prices on a third of its products, and it is now assessing whether further price adjustments will be necessary in light of the new tariff. E.l.f. Beauty has been actively working to reduce reliance on Chinese manufacturing, decreasing it from nearly 100% to about 80% over the past five years. While this diversification effort continues, DA Davidson acknowledged the significant impact of the tariffs on E.l.f. Beauty's stock. Meanwhile, analysis from Canaccord suggests that despite the immediate stock sell-off, this could represent a buying opportunity, given E.l.f. Beauty's history of navigating tariff impacts successfully.